63
1
Monitor adherence and
response to therapy
1
Monitor adherence and
response to therapy
1
Monitor adherence and
response to therapy
2a
Optional goal:
LDL-C <55 mg/dL and
non–HDL-C <85 mg/dL
Patient unable to tolerate,
obtain, or adhere to
PCSK9 mAb therapy?
NO
Optional goal:
apoB <55 mg/dL
Optional apoB goal
<70 mg/dL
2a
Add ezetimibe,
a PCSK9 mAb,
and/or bempedoic acid
AND
YES
2a
Initiate inclisiran* to
lower LDL-C
NO
LDL-C <70 mg/dL
and non–HDL-C
<100 mg/dL?
